Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, ...
VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced positive preclinical results for its novel small molecule, DB …